Heron Therapeutics, Inc.
HRTX
$0.41
$0.011.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -297.44% | -48.71% | 51.45% | 98.07% | 90.38% |
| Total Depreciation and Amortization | -2.63% | -7.14% | -10.21% | -16.16% | -17.98% |
| Total Amortization of Deferred Charges | -19.96% | -14.98% | 10.80% | 110.38% | 141.12% |
| Total Other Non-Cash Items | 51.80% | 40.47% | 24.57% | -51.83% | -46.38% |
| Change in Net Operating Assets | 54.86% | -15.49% | -4,696.85% | -1,286.16% | -542.49% |
| Cash from Operations | 7.41% | -22.47% | -263.96% | -35.04% | 49.58% |
| Capital Expenditure | 67.00% | 81.42% | 27.54% | 17.50% | -37.40% |
| Sale of Property, Plant, and Equipment | -18.84% | 262.96% | 738.46% | 515.38% | 430.77% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -37.82% | -20.42% | 14,452.77% | 197.18% | 232.01% |
| Cash from Investing | -35.07% | -14.45% | 2,235.26% | 187.00% | 212.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,971.30% | 2,094.89% | 2,832.45% | -95.51% | -96.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -316,050.00% | -488.89% | 100.00% |
| Cash from Financing | 1,341.29% | 1,434.79% | 1,943.44% | -97.65% | -98.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 679.85% | 198.96% | 290.03% | -137.98% | 82.21% |